Baird analyst Michael Ha lowered the firm’s price target on Tenet Healthcare (THC) to $167 from $195 and keeps a Neutral rating on the shares as part of an update on the managed care and healthcare facilities group. The firm is increasingly cautious on Medicaid and the healthcare exchange.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on THC:
- Tenet Healthcare’s Strong Financial Performance and Strategic Initiatives Drive Buy Rating
- Tenet Healthcare price target lowered to $208 from $215 at Barclays
- Bill would force hospitals to warn if not equipped to save preemies, WSJ says
- Tenet Healthcare price target raised to $200 from $185 at Raymond James
- Tenet Healthcare price target raised to $188 from $180 at Guggenheim